Health Care·Biotechnology·$8.0B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.49 | N/A | -11.87% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.49 | N/A | -11.87% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Overall, management expressed concerns about market conditions affecting performance. They reiterated their commitment to long-term goals despite short-term setbacks.
Management highlighted ongoing challenges in the current market environment.
They emphasized the need for continued focus on product development.
The earnings report indicates that Krystal Biotech is still facing challenges, as evidenced by the missed EPS target. The stock reacted negatively, dropping 6.42%, likely due to investor concerns over the company's current performance and lack of revenue updates. Without guidance, investors may remain cautious about the company's near-term prospects.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
JOHNSON CONTROLS INT
Nov 3, 2020